- Source type
- Government
- Access type
- Official
- Publisher
- U.S. Food and Drug Administration
- Date
- 2026-07-02
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
94
U.S. health regulator
- Publisher type
- Regulator
- Bias profile
- Low
This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 98/100
- Primary Anchor
- Clinical outcomes
- 84/100
- Strong Support
- Mechanism
- 68/100
- Context Source
- Safety
- 95/100
- Primary Anchor
- Consumer context
- 68/100
- Context Source
- Trial discovery
- 68/100
- Context Source
Best used for
- Approvals
- Labels
- Safety communications
Weak for
- Comparative effectiveness
- Consumer experience
Used in Viral Vitalism
FDA Flagged a Serious Omnipod Insulin-Delivery Recall
Roles: Primary source
Related studies
No structured study record is currently attached to this source.
Related sources
FDA: Neurologic complications after anesthesia linked to genetic variant
Primary FDA alert for rare anesthesia-linked neurologic outcomes in patients of maternal Venezuelan ancestry.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
AABB: FDA warns against use of unapproved HCT/Ps
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- AABB
- Access
- Publisher
- Usage
- 1 connection
Beyond Type 1: FDA approves Tzield for pediatric stage 3 T1D
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- Beyond Type 1
- Access
- Publisher
- Usage
- 1 connection
FDA Q&A: Proposed order for over-the-counter sunscreen
U.S. Food and Drug Administration used across the Viral Vitalism evidence library.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 9 connections
FDA: 2026 Safety and Availability Communications
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection